Clinical Trial Update: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD [Phase 3]

View source ↗

Summary

This is a Phase 3 randomized trial update evaluating dapagliflozin for renal and cardiovascular outcomes in patients with severe chronic kidney disease, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Heart Failure
• Renal Transplant Failure

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Kidney Disease, Chronic, Renal Transplant Failure | Phase 3 | Status: ENROLLING_BY_INVITATION